ReviewFrontiers in microbiology2025
Multidrug-resistant Gram-negative bacteria in lung transplantation: a narrative review of infectious complications and current management.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances in consistency and variability inJournal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant Gram-negative bacterial (MDR-GNB) infections represent a major challenge in lung transplantation (LuTx), due to their possible association with poor clinical outcomes and the limited availability of effective antimicrobial agents. Nevertheless, MDR-GNB colonization or infection is no longer considered an absolute contraindication to transplantation. Recent recommendations issued by leading societies in clinical microbiology and infectious diseases, national expert groups, and transplant medicine professionals provide updated recommendations on antimicrobial strategies, encompassing both established and newly approved agents. Following an overview of the epidemiology of infections in LuTx recipients, with a focus on the specific impact of MDR-GNB, this review aims to explore current evidence on diagnostic approaches, prophylactic measures, and therapeutic management. Remaining knowledge gaps in this area are also highlighted, emphasizing the need for further research to optimize prevention and treatment strategies in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.